
SUMMARY


[0004] Provided herein are methods of treating depression, e.g., major depressive disorder, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the formula



(Compound 1)

or a pharmaceutically acceptable salt thereof. In further ~~embodiment~~examples, Compound 1 is administered using an episodic dosing regimen. In the methods described herein, Compound 1 or a pharmaceutically acceptable salt thereof can be administered for a specified period of time, e.g., 14 days. Following such specified periods of time, the subject is not dosed with the compound for another specified period of time, e.g., at least a period of e.g., about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, or about 6 weeks.


[0004a] In one aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days.


[0004b] In another aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days.


[0004c] In a further aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days and about 30 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.


[0004d] In another aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days and about 50 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

[0005] In one ~~aspect~~example, described herein is a method of treating depression, e.g. major depressive disorder (MDD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount, e.g., about 30 mg, of a compound of the formula:




(Compound 1)

once a day for 14 days. In another ~~aspect~~example, described herein is a method of treating depression, e.g. major depressive disorder (MDD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount, e.g., about 50 mg, of Compound 1 once a day for 14 days. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 30 mg-40 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 30 mg-50 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 40 mg-60 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 45 mg-55 mg. In some ~~embodiment~~examples, the therapeutically effective

amount of the compound is 30 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 50 mg. In some ~~embodiment~~examples, the major depressive disorder is severe major depressive disorder (SMDD). In some ~~embodiment~~examples, the subject exhibits a reduction in depression-related symptoms. In some ~~embodiment~~examples, the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.

[0006] In another ~~aspect~~example of the methods provided herein, described herein is a method of treating depression, e.g. major depressive disorder, comprising the steps of:

(i) administering once daily to the subject a therapeutically effective amount, e.g., about 30 mg, of a compound of the formula:




(Compound 1)

once a day for 14 days; and

(ii) re-administering once daily to the subject a therapeutically effective amount, e.g., about 30 mg, of Compound 1 for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

[0007] In another ~~aspect~~example of the methods provided herein, described herein is a method of treating depression, e.g. major depressive disorder, comprising the steps of:

(i) administering once daily to the subject a therapeutically effective amount, e.g., about 50 mg, of a compound of the formula:



(Compound 1)

once a day for 14 days; and

(ii) re-administering once daily to the subject a therapeutically effective amount, e.g., about 50 mg, of Compound 1 for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

[0008] In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 20 mg-40 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 20 mg-50 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 40 mg-60 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 45 mg-55 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 30 mg. In some ~~embodiment~~examples, the therapeutically effective amount of the compound is 50 mg. In some ~~embodiment~~examples, the major depressive disorder is severe major depressive disorder. In some ~~embodiment~~examples, the subject exhibits a reduction in depression-related symptoms. In some ~~embodiment~~examples, the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment. In some ~~embodiment~~examples, the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.

BRIEF DESCRIPTION OF THE DRAWINGS


[0009] FIG. 1 depicts an exemplary study design for treating MDD with Compound 1.

[00010] FIG. 2 depicts exemplary HAM-D total score LS mean changes from baseline to Day 15 in patients in a Phase 3 study of Compound 1 in Major Depressive Disorder.

CLAIMS

What is claimed is:


1. Use of ~~A method of treating major depressive disorder in a subject in need thereof, comprising administering to the subject about 40 mg of~~ a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days.

2. Use of ~~A method of treating major depressive disorder in a subject in need thereof, comprising administering to the subject about 50 mg of~~ a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days.

3. The ~~method~~use of claim 1 or 2, wherein the major depressive disorder is severe major depressive disorder.

4. The ~~method~~ use of any one of claims 1-3, wherein the subject exhibits a reduction in depression-related symptoms.

5. The ~~method~~ use of any one of claims 1-4, wherein the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline.

6. The ~~method~~ use of any one of claims 1-5, wherein the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment.

7. The ~~method~~use of any one of claims 1-6, wherein the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment.


8. The ~~method~~use of any one of claims 1-7, wherein the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment.

9. The ~~method~~use of any one of claims 1-8, wherein the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment.

10. The ~~method~~use of any one of claims 1-9, wherein the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.

11. Use of~~A method of treating depression in a subject in need thereof, the method comprising the steps of:~~

~~(i) administering once daily to the subject about 40 mg of~~ a compound of the formula:




(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days~~;~~ and

~~(ii) re-administering once daily to the subject~~ about 30 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

12. Use of~~A method of treating depression in a subject in need thereof, the method comprising the steps of:~~

~~(i) administering once daily to the subject about 50 mg of~~ a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days~~;~~ and

~~(ii) re-administering once daily to the subject~~ about 50 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

13. The ~~method~~use of claim 11 or 12, wherein the major depressive disorder is severe major depressive disorder.

14. The ~~method~~use of any one of claims 11-13, wherein the subject exhibits a reduction in depression-related symptoms.

15. The ~~method~~use of any one of claims 11-14, wherein the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline.

16. The ~~method~~use of any one of claims 11-15, wherein the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment.

17. The ~~method~~use of any one of claims 11-16, wherein the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment.

18. The ~~method~~use of any one of claims 11-17, wherein the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment.

19. The ~~method~~use of any one of claims 11-18, wherein the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment.

20. The ~~method~~use of any one of claims 11-19, wherein the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.